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Psoriasis is an inflammatory and erythematous scaly disease that involves the 
skin, joints, and nails. Its prevalence is 1–3%. The incidence of nail involvement in 
psoriasis patient ranged between 15 and 69%. Nail psoriasis is an important problem 
affecting patients both functionally and psychologically. Patients with nail psoriasis 
can develop a wide variety of nail changes, such as pitting, onycholysis, subungual 
hyperkeratosis, nail discoloration, crumbling and leukonychia, oil spots, and 
splinter hemorrhages. Nail psoriasis is also strongly associated with psoriatic arthri-
tis. It has been estimated that 80–90% of patients with psoriatic arthritis develop 
nail involvement. Dermoscopy can be useful in the evaluation of psoriatic nail when 
there are no typical clinical features. Dermoscopic findings vary depending on the 
affected area of the nail. Capillaroscopy and confocal microscopy help in the diagno-
sis. Treatment of the disease includes avoidance of trauma to the nails and different 
therapeutic approaches with topical, intralesional injections and systemic agents.
Keywords: nail psoriasis, etiology, diagnosis, treatment
1. Introduction
Psoriasis is a common skin disease characterized by inflammation and a chronic 
course with exacerbation and remission episodes. The worldwide prevalence is 
approximately 1–2% [1]. The most common involvement of the nail is encountered 
in psoriasis among all skin diseases. The nail changes may be accompanied by the 
skin lesions, but in some patients they occur alone. Regarding the literature, the 
prevalence of the nail involvement is between 10 and 83% [2]. Isolated nail involve-
ment is observed only in 1–5% of all psoriatic patients [2, 3]. There is no difference 
between the genders considering the prevalence of the nail involvement. The inci-
dence of the nail involvement in children is between 7 and 17%. The cutaneous pso-
riasis has usually a more severe course in patients with the nail involvement [1]. The 
changes affecting the nails are encountered in 90% of the psoriatic patients during 
their lifetime. The prevalence of the nail psoriasis is higher in patients with psoriatic 
arthritis. The nail involvement is between 75 and 86% in patients with arthropathic 
psoriasis [4]. It was reported that nail psoriasis is more common in hands compared 
to the feet. The nail involvement in psoriasis is concomitant with insertion points of 
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tendons and ligament inflammation. Several studies focused on the co-occurrence 
of nail involvement, and psoriatic arthritis confirmed the anatomical connection 
between the nail matrix and the enthesis of the distal interphalangeal (DIP) joint 
extensor. In the light of these observations, it is believed that the nail lesions are 
caused by a reaction, which is developing as a reaction to the abnormal tissue stress 
and inflammation in the nail-joint region, and not as an autoimmune response [5]. 
Gupta et al. investigated the toenails of 561 psoriatic patients and determined nail 
disorders in 47% of them [6]. Larsen et al. determined nail changes in 82.3% of 79 
psoriatic patients and Salmon et al. in 78.3% of 106 psoriatic patients [7, 2]. The nail 
lesions emerge usually 10 years later than the skin lesions. This explains why nail 
psoriasis is less common in children.
2. Etiology and pathogenesis
The pathophysiology of nail psoriasis was first described by Nardo Zaias in 1969 
[1]. The etiology of psoriasis is not fully elucidated yet. The genetic susceptibility 
may play a role, but also environmental factors, drugs, infections, trauma, and 
psychogenic factors may trigger the disease.
2.1 Genetic factors
The role of genetic factors has been a matter of research in the past decades. 
In his study, Lomholt demonstrated the presence of psoriasis at least in one of the 
first- and second-degree relatives of 91% of the psoriatic patients [4].
Genome-wide association studies have identified nine chromosomal loci 
(PSORS1 through PSORS9) that can be linked to psoriasis. Human leukocyte antigen 
(HLA)-Cw6, involved in antigen presentation, seems to be a susceptible allele located 
on PSORS1. HLA-CW6 allele is directly associated with the genetic base of the dis-
ease, and it is a major region leading the immunopathogenetic model. The HLA-CW 
602 allele, which is localized in this locus, has a significant co-occurrence pattern 
with psoriasis. Other candidate genes, which may be related to psoriasis, are HLA-C, 
corneodesmosin, and HCR. Studies showed a co-occurrence with PSORS1 gene on 
the chromosome 6p12. However, HLA-C seems to be a gene marker rather than an 
etiological factor. In cases, in which there is a co-occurrence with HLA antigens, the 
rates of the nail involvement and arthritis are higher than the other types [8].
2.2 Immunologic factors
The tissue reaction seen in psoriasis involves a complex immunological reaction, 
which ends up with epidermal hyperproliferation along with severe inflammation 
and abnormal keratinocyte differentiation. The activation of the keratinocytes and 
dendritic cells follows particularly the activation of the T cells, which migrate to 
the skin. Certain functional T-cell subpopulations like Th1 and Th17 emerge under 
the influence of some cytokines like interleukin (IL)-12 and IL-23. These media-
tors stimulate the secretion of pro-inflammatory cytokines like the tumor necrosis 
factor-alpha (TNF-α), IL-17, IL-20, and IL-22. The secretion of the adhesion 
molecules and other mediators aggravates the inflammatory process in psoriasis. 
As a result of this cascade, neutrophil migration emerges, which ends up with the 
development of the epidermal microabscess. The increase of the proliferative activ-
ity and the abnormal maturation of the keratinocytes lead to hyperparakeratosis, 
which is characteristic for psoriasis. Studies showed that TNF-α, nuclear factor 
kappa B, IL-6, and IL-8 were increased in the affected nail tissue [8, 9].
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It is believed that certain fungal infections like Candida albicans and some 
other bacterial infections play a role in the exacerbation of psoriasis. Thereby, the 
systemic inflammation is triggered by the extensive expression of the inflamma-
tory cytokines. Candida stimulates the superantigen production and the cytokine 
secretion, which initiates the psoriatic process as a result of the non-specific T-cell 
activation [10].
2.2.1 Predisposition factors
The factors affecting the onset and the exacerbations of the disease vary from 
person to person. Trauma is among the factors, which trigger psoriasis. These 
factors are radiation (UV, X-ray), dermabrasion, burns, tattoos, vaccines, and 
inflammatory skin diseases [11]. It is well-known for a long time that infections may 
trigger and exacerbate psoriasis. Particularly, group A beta-hemolytic streptococci, 
Staphylococcus aureus, and Candida albicans are the most common microorganisms 
[12, 13]. Pregnancy may decrease the activity of the disease. Chronic plaque psoriasis 
is the most commonly worsening form of psoriasis during the pregnancy. It was also 
reported that psoriatic arthritis is aggravated during pregnancy [14]. Regarding the 
environmental factors, emotional disturbances are the most commonly blamed fac-
tor. Stress, anxiety, and depression may be the triggering factor for psoriasis. Stress 
can play a role not only at the onset of the disease but also in exacerbations [15].
Drugs currently known for affecting psoriasis are the following: beta-adrenergic 
receptor blockers, non-steroidal anti-inflammatory drugs, angiotensin-converting 
enzyme inhibitors, tetracyclines, lithium, and interferons. Certain topical antipso-
riatic agents like tar and anthralin may sometimes cause exacerbations in patients, 
who are in the active stage of the disease [16]. The relationship between the climatic 
features and psoriasis is well-known. In some patients, the lesions may be aggra-
vated by the sunlight [17, 18]. The relationship between psoriasis and obesity was 
first reported by Lindegard [19]. Several studies showed that obesity is a risk factor 
for psoriasis. The demonstration of the pro-inflammatory character of obesity and 
the action of the adipose tissue like an endocrine and immune organ explained its 
role in psoriasis. Weight loss and diet restriction decrease TNF-α and IL-6 con-
centrations and consequently decrease the oxidative stress. It was reported that 
high-calorie diets and some foods that contain PUFA, such as nuts and fish, increase 
the severity and incidence of psoriasis. Therefore, it is believed that low-calorie 
diets may contribute to the remission of the disease [19]. Some studies reported that 
particularly smoking and alcohol had a correlation with psoriasis [12].
2.3 The components of the nail unity
The nail folds are soft tissue structures that protect the lateral and proximal 
edges of the nail plate. The nail originates from the matrix and is attached to the 
nail bed and ends up with a free margin at the distal side. The term “nail units” 
comprises all nail structures and involves nail fold, eponychium, paronychium, 
hyponychium, nail bed, and nail plate with proximal and lateral nail folds and soft 
tissue structures [20–23].
3. Pathophysiology
The main findings of the nail psoriasis are pitting, onycholysis, thickening of 
the nail plate, oil-drop discoloration on the nail bed, transverse ridges, Beau’s lines, 
splinter hemorrhages, subungual hyperkeratosis, and psoriatic paronychia [24].
Tailored Treatments in Psoriatic Patients
4
The histopathological features of the nail psoriasis are neutrophilic inflamma-
tion, psoriasiform hyperplasia, and dilated and inflamed capillaries. The granular 
layer of the hyponychium disappears in the psoriatic nail, and a granular layer 
emerges in the nail matrix and nail bed. The hyperkeratosis is usually mild or 
moderate. Spongiosis is common. Parakeratosis foci may emerge on the dorsal, 
medial, or ventral segments of the nail plate and may cause pitting, leukonychia, 
and onycholysis. Before the histopathological diagnosis of the nail psoriasis, a 
differential diagnosis regarding onychomycosis with the help of the Periodic acid 
Schiff stain is recommended [25].
In the finger nail psoriasis, the findings by order of frequency are pitting, red-oily 
spots, onycholysis, subungual hyperkeratosis, and splinter hemorrhage. In the toenail 
psoriasis, the common findings are subungual hyperkeratosis and diffuse yellow-
brown discoloration in the nail plate, onycholysis, and splinter hemorrhage [26, 27].
3.1 The characteristics of the nail psoriasis
Matrix: Punctate depressions on the nail surface due to abnormal keratinization of 
the nail plate. Pitting occurs as a result of the parakeratosis in the superficial matrix. It 
is encountered also in other diseases affecting the matrix keratinization of the proxi-
mal nail (e.g., alopecia areata, eczema). The white-opaque appearance of the paraker-
atotic cells in the distal and medial segment of the matrix in the shape of a transverse 
band is called leukonychia. Red spots in the lunula a sign of the active distal matrix 
psoriasis and emerge a result of the vasodilatation and thinning of the suprapapillary 
plate. The involvement of the proximal nail matrix causes lesions such as transverse 
striations on the surface of the nail plate, longitudinal grooves, and superficial pitting. 
Beau’s lines are common in the acute erythrodermic psoriasis [1, 28].
Nail Bed: The psoriatic plaques in the distal matrix and nail bed are called oil-
drop spots (salmon spots). It emerges with the serum and debris migration to this 
region as a result of the local detachment of the nail plate from the nail bed. This 
finding is rare in other diseases except for psoriasis, and it is useful in the diagnosis 
of the psoriatic nail. Following the extension of the salmon spot to the hyponych-
ium, parakeratosis resolves, and psoriatic onycholysis develops [28].
Splinter hemorrhages develop as a result of the erythrocyte extravasation from 
the dermal ridges located between the epidermis and the nail plate. This finding is 
similar to the Auspitz phenomenon in the skin. The “Auspitz sign” refers to the bleed-
ing that can occur when the surface of a scaling rash has been removed. Onycholysis 
is defined as the detachment of the nail plate from the nail bed. The detachment area 
has a whitish appearance due to the air accumulation. The onycholytic area can be 
distinguished from the normal nail with its erythematous appearance. Onycholysis 
and subungual hyperkeratosis are predictors of the hyponychium psoriasis [26]. 
Pustular psoriasis in the nail bed and nail folds, nail loss (anonychia), onychomade-
sis, and absence of the nail growth are other findings in the psoriatic nail [20].
Psoriasis in the proximal nail fold: The cuticle is damaged, and there is a typical 
appearance of the chronic paronychia along with the erythema, squam, and edema 
in the proximal nail fold. Hyponychium involvement causes subungual hyperkera-
tosis and onycholysis [29].
4. Grading and scoring of psoriatic nail
Several numeric scales were developed to determine the numeric equivalent of the 
response to the treatment of psoriasis. These numeric scales enable an easier follow-up 
of the disease and of the response to the treatment. The Nail Psoriasis Severity Index 
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(NAPSI) is a scoring system developed by Riche and Scher in 2003 [30]. According 
to this system, the nail matrix findings (pitting, leukonychia, red spots in lunula, 
increased friability of the nail plate) and the nail bed findings (onycholysis, splinter 
hemorrhage, oil drop, and nail bed hyperkeratosis) are scored as follows: If any of 
these signs is present in all four quadrants, a score of 4 is given. A score of 0 represents 
no signs in any quadrant. Each nail is evaluated for a matrix and a nail bed score of 
0–4. They are combined to yield a maximal score of 0–8 for each nail. [26] After the 
scoring is completed, the sum of the scores is recorded as the NAPSI score. The NAPSI 
scores calculated for each nail are summed up to find the total NAPSI score. The single 
nail score can be between 0 and 8 and the total score between 0 and 160. Regarding 
the Cannavo’s scoring system, the nail findings are scored between 0 and 3, and the 
scoring is done according to the presence or absence of the findings [31].
The modified NAPSI, which is described by Parrish et al., is based on the scoring 
of the common findings [32]. The scoring is done between 0 and 3 according to the 
number of pitting. The modified NAPSI score for 1 finger can be between 0 and 14 
and for 10 fingers between 0 and 140 [33].
5. Diagnosis
As the nail involvement pursues skin psoriasis, its diagnosis is rather easy. 
However, 5% of the cases are isolated nail psoriasis, and the diagnosis may become 
difficult. Like in the skin, biopsy has a diagnostic value. Biopsy sampling should be 
taken from the proximal segment, and it should enclose partly the subungual soft 
tissue to detect the matrix involvement [34].
Except for biopsy, dermoscopy, and videodermoscopy may support the clini-
cal findings and thus the diagnosis. Videodermoscopy provides a 1000x higher 
magnification compared to the dermoscopy, and the images can be examined 
on a monitor. It is beneficial particularly for the observation of the capillaries in 
the hyponychium. The capillaroscopy is used to determine the dilated capillaries 
in the proximal nail fold. The vascular structures may be better visualized with 
the confocal microscopy. High-frequency ultrasonography (USG) can be useful 
only if performed by experienced hands. The increase in the blood flow and the 
thickening of the nail bed can be determined with the Doppler USG. The opti-
cal coherence tomography is a noninvasive imaging method and has a relatively 
higher resolution and thus is effective in the detection of the changes in the nail 
plate and vessels [35].
6. Differential diagnosis
The nail psoriasis is usually diagnosed with the help of the clinical findings. 
The differential diagnosis between nail psoriasis and other diseases, which causes 
nail dystrophy (e.g., onychomycosis), can be done with biopsy and histopathologi-
cal examination. Klaassen et al. reported that the prevalence of onychomycosis is 
higher in psoriatic patients compared to the patients without psoriasis [36].
Several diseases affecting nails can be confused with the psoriatic nail. 
Following conditions should be considered during the differential diagnosis: 
trauma, onychomycosis, pityriasis rubra pilaris, palmoplantar keratoderma, chronic 
venous stasis, many drugs, alopecia areata, eczema, lichen planus, Darier disease, 
pachyonychia congenita, and Hailey-Hailey disease [37].
Besides, toenail dystrophy is particularly more common in elderly people. 
Peripheral artery disease, chronic venous stasis, peripheral neuropathy, and certain 
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drugs (beta-blockers, lithium, interferon-α) should also be considered during the 
differential diagnosis [38].
Pitting, which can be encountered in alopecia areata, lichen planus, and eczema, 
is one of the most common nail findings in psoriasis, and it is relatively more deep-
seated in psoriasis compared to other diseases. The dorsal pterygium and longitudi-
nal fissures are rather typical findings in lichen planus [38].
Onycholysis, which is another typical finding in the nail psoriasis, emerges first 
in the distal segment of the nail and extends in time to the proximal segment. This 
finding can be encountered also in nail traumas, fungal infections, and thyroid 
disorders [39].
Beau’s lines characterized by the transverse lines on the nail can emerge in 
Raynaud’s disease as a result of the exposure to the cold [40].
As the splinter hemorrhages, which progress with linear spotlike bleedings, 
can also emerge in vasculitis, bacterial endocarditis, and traumas. Therefore, they 
should be considered during the differential diagnosis [1].
7. Treatment
Regarding the treatment of nail psoriasis, the protection of the nail from 
the external physical and chemical factors is critical. Manicure and pedicure 
should be avoided due to the risk of the Köbner reaction. Candida infections are 
more common compared to the dermatophyte infections in the psoriatic nails. 
Onychomycosis, which may accompany nail psoriasis, should be diagnosed and 
treated before starting the psoriasis treatment [41].
As nail is a slow-growing cutaneous appendage, a long-term treatment should be 
considered in the nail psoriasis. The outcome of any treatment cannot be evaluated 
before 3–6 months, and the achievement of a maximum therapeutic success can 
be evaluated only after 1 year or longer [42]. There are various alternatives for the 
treatment. The decision on a treatment method depends on several factors such as 
the severity of the nail involvement and its effects on the quality of life, presence of 
other skin lesions, presence of psoriatic arthritis, comorbidities, occupation, age, 
patient’s preferences, potential risks, and cost.
7.1 Topical treatments
Although the nail psoriasis is usually resistant to the topical treatments, it 
should be the first choice if the skin is also involved. As the applied drug can hardly 
penetrate into the matrix in the presence of subungual hyperkeratosis and pitting, 
resistance to the treatment is the rule. Nevertheless, at least a 3-month application is 
needed to observe the effect of the topical antipsoriatic agent [43].
7.1.1 Corticosteroids
The most common treatment agents in the nail psoriasis are the topical cortico-
steroids. If the matrix and nail bed are involved, high-potency topical steroids are 
applied once or twice a day to the nail plate and proximal nail fold. All high-potency 
steroids may cause atrophy and hyperpigmentation if they come into contact with 
the skin during the treatment [44]. In the recent years, studies showed that topical 
opaque nail polish formulations, which contain 8% clobetasol propionate, were 
more effective than the steroids. It was reported that this product, which was safe, 
effective, and easily applicable due to the cosmetic formulation, did not cause 
periungual skin atrophy like topical cream forms [45, 46].
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7.1.2 Calcipotriol
Topical calcipotriol is used in the treatment of the chronic plaque psoriasis. It 
is effective on the thickening of the nail plate and subungual hyperkeratosis. Main 
side effects are local skin irritations. Vitamin D3 and its analogs are well established 
in the therapy of psoriasis vulgaris [47].
7.1.3 5-Fluorouracil (5-FU)
One study conducted on subject groups showed that topical 5-FU solutions with 
20% urea were effective on pitting, subungual hyperkeratosis, and oil-drop appear-
ance [48].
7.1.4 Cyclosporine
It is a calcineurin inhibitor, and cyclosporine is good effect on psoriasis. 
Although topical use of cyclosporine in nail psoriasis has been discussed, only 
limited success could be achieved with 10% oily preparations [49].
7.1.5 Anthralin
Anthralin is an effective treatment of skin lesions in psoriasis. In one uncon-
trolled study, anthralin in a Vaseline-containing ointment was applied to 20 pso-
riasis patients with nail involvement. Therapy was applied to the affected nail bed 
once daily, and 60% of the patients showed good improvement of onycholysis. The 
most important complication of this treatment is pigmentation [50].
7.1.6 Tazarotene
Tazarotene is a synthetic retinoid with anti-inflammatory and antiproliferative 
actions on keratinocytes. Gel formulations of 0.1% tazarotene were used in the topical 
treatment of the nail psoriasis, and varying results were achieved. It may cause certain 
side effects like erythema and burning sensation in the periungual region [51].
7.2 Intralesional treatments
The perilesional injections constitute another form of the local treatment 
(Figure 1). During this treatment, a maximum efficacy is obtained with a minimum 
dose of the drug, which is applied into the lesion. Intralesional injections of cortico-
steroids are the most common method. As injections into the matrix and under the 
nail bed are painful, local anesthesia is necessary. A proximal finger block or hand 
and wrist block can be preferred. Cold application to the proximal nail fold before 
the injection may reduce the pain. The injection is usually done with a 30G needle. 
0.05–0.1 triamcinolone acetonide suspension is injected into both sides of the 
proximal nail fold monthly for 6 months. This treatment is most effective on salmon 
spots and subungual hyperkeratosis [52]. Possible complications of this treatment 
are subungual hematoma, transient nail dystrophy, atrophy of the terminal phalanx 
bone, extensor tendon rupture, and epidermoid inclusion cysts [53].
In nail psoriasis, methotrexate (MTX) and cyclosporine may be applied to 
the proximal fold with an intralesional injection technique. In patients with nail 
psoriasis, who had pitting and subungual hyperkeratosis on a single nail, Sarıcaoğlu 
et al. applied 2.5 mg MTX to two lateral points of the proximal fold once weekly 
for 6 weeks and observed no recurrence during the 2-year follow-up period [54]. 
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Mittal et al. conducted a study on 20 patients with nail psoriasis and compared the 
efficacy of intramatricial triamcinolone acetonide, methotrexate, and cyclosporine 
injections and found out that methotrexate and corticosteroid had comparable 
efficacies. They also reported that the side effects of MTX were less frequently and 
cyclosporine was less effective and caused pain, which lasted a couple of days [55].
7.3 Phototherapy and photochemotherapy
The combination of oral psoralen and UVA, which is also called PUVA is a 
photochemotherapy method. It was reported that it provided successful results in 
patients with nail bed involvement, which ended up with onycholysis and salmon 
patches. However, it was also stated that it was not effective on pitting, which is an 
indicator of matrix involvement. Marx and Scher conducted a study on ten patients 
and showed that PUVA improved all nail lesions except pitting in 95% of the 
patients [56]. Except for oral psoralen, local PUVA treatment with the topical 1% 
8-methoxypsoralen is an alternative for the treatment of the psoriatic nail [57]. As 
the penetration of the narrow band UVB is rather superficial, it is not an effective 
option for the palmoplantar psoriasis lesions and nail involvement [58].
7.4 Ionizing radiations
Superficial radiotherapy is the application of the electromagnetic radiation on 
the skin surface. It is rarely used in the treatment of psoriatic nail. It was reported 
in one study that it decreased the nail thickness in the patients with subungual 
hyperkeratosis [59]. Grenz rays and electron beam therapy are low-voltage radiation 
treatments, which do not penetrate the subdermal structures. In patients older than 
30 years, Grenz rays [maximum 10Gy (1000 rad)] to each area can be applied. If it 
is applied to healthy areas and surrounding skin, it may cause hyperpigmentation 
and malignant skin tumors in the late stage [60].
Figure 1. 
(a) Subungual hyperkeratosis with pitting in fingernails before the MTX intramatricial injection. (b) Improvement 
of nail dystrophy was observed after 6 months of follow-up.
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7.5 Laser therapy
As angiogenesis is considered as a pathogenetic factor for psoriasis, pulsed-dye 
laser (PDL) was used in several studies to treat nail psoriasis. The target of the laser 
therapy is the matrix and the dilated capillaries in the nail bed. A PDL laser at wave-
length 595 nm and with a spot size of 7 mm was usually preferred. It was observed 
that the pain increased along with the pulse duration [61].
7.6 Systemic therapies
Several systemic agents are used for the treatment of the nail psoriasis. The most 
commonly used drugs are MTX, retinoids, and cyclosporine. However, they are 
usually preferred in patients with severe dermal and articular involvement. They 
are not the first choice for psoriasis, which affects only nails.
7.6.1 Retinoids
Acitretin is effective on the thickening of the nail plate, subungual hyperkera-
tosis, Hallopeau acrodermatitis, and the nail involvement in pustular psoriasis. 
Its usual dose is 0.5–1 mg/kg/day. Although etretinate decreases significantly the 
thickening of the nails, it was reported that it increased pitting and onycholysis 
[43, 62].
7.6.2 Methotrexate
Methotrexate (MTX), which is an antimetabolite agent, slows down the nail 
growth and therefore delays the healing process in the nail lesions. Intralesional 
MTX injections are preferred to the oral administration due to the side effects like 
hepatotoxicity and pancytopenia, and studies reported improvement in the affected 
nail with intralesional injections [54, 55]. MTX is used in the Hallopeau acroder-
matitis and the affected nails in pustular psoriasis, which is resistant to the topical 
treatments [49].
7.6.3 Cyclosporine
The calcineurin inhibitor cyclosporine A is another systemic antipsoriatic agent 
and has powerful immunosuppressive activity. Its positive effect on cutaneous 
psoriasis and nail psoriasis was clearly demonstrated in both uncontrolled and 
comparative studies [63]. Its recommended dose is 3–5 mg/kg. Cyclosporine A 
treatment is limited to 6–12 months due to the potential of serious side effects such 
as kidney function disorder and arterial hypertension.
Fumaric acid esters can also be used in the treatment of psoriasis. Its efficacy on 
the affected nails was demonstrated in a case report [64].
Leflunomide is an antirheumatic agent effective in psoriatic arthritis. It was also 
reported that it is effective in nail psoriasis [65].
Apremilast is an oral phosphodiesterase-4 inhibitor, which decreases the expres-
sion of various pro-inflammatory mediators. Its mechanism of action is related 
rather to anti-inflammatory activity than the immunosuppressive activity. It has a 
preferable side effect profile [66]. Studies reported that it provided improvement in 
the skin and nail psoriasis after a 32-month treatment [67].
Tofacitinib is an oral Janus kinase inhibitor, which exhibits its effects through the 
JAK–STAT pathway. It was demonstrated that it was effective on the nail lesions of 
psoriasis and alopecia areata [68].
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7.7 Biologic therapy
As there are only a limited number of studies focused on the use of biologic 
agents in the nail psoriasis, experience about their efficacy is limited. The number 
of the studies focused on the use of the biologic agents in the treatment of psoriatic 
nails will increase depending on their increasing use in psoriasis and psoriatic 
arthritis. In the studies, which compared the biologic agents with the conventional 
systemic drugs, it was shown that the efficacy of the biologic agents was lower and 
the improvement in the NAPSI score started approximately after 47 months [69]. 
Their high cost is another factor, which limits their usage.
Infliximab is a mouse-derived chimeric monoclonal antibody, which antago-
nizes membrane-bound and soluble TNF-α, and it is the most fast-acting TNF-α 
inhibitor. The recommended dose is 5 mg/kg IV at 0, 2, and 6 weeks and thereafter 
once every 8 weeks. In a study conducted on 38 patients, who had nail psoriasis, an 
almost complete improvement was achieved after 38 weeks [70].
Adalimumab is a human monoclonal IgG1 antibody against TNF-α. It has a 
similar mechanism of action to infliximab, but it does not increase the incidence of 
onychomycosis like infliximab. Van den Bosch et al. reported a 20% improvement in 
the NAPSI score with a dose of 40 mg/week after 20 weeks [71].
Etanercept blocks TNF-α depending on the fusion between the Fc portion of the 
IgG1 antibody and TNF receptor. In a randomized study, 564 patients with moder-
ate psoriasis and nail involvement were treated with etanercept, and the NAPSI 
score decreased about 51% after 54 weeks [72].
The new-generation biologic agents inhibit interleukins, which affect the psori-
atic process. However, their immunosuppressive efficacy is weaker than the TNF- α 
inhibitors. The IL-17 inhibitors secukinumab, ixekizumab, and brodalumab were 
recently introduced in the therapy. Ustekinumab is a monoclonal antibody targeting 
the p40 subunit of IL-12/23. Patsatsi et al. administered 45 mg ustekinumab at the 
baseline, in the fourth week and afterwards in every 12 weeks, and reported that the 
NAPSI scored was declined from 73 to 0 after 40 weeks [73].
Biologic agents and interleukin inhibitors are not the first choices in the treat-
ment of the nail psoriasis due to their side effect potential. The treatment should be 
started with topical agents. The conventional systemic antipsoriatic agents should 
be administered if there is no improvement after 4–6 months with topical agents. 
The biologic agents should remain as the last choice.
The nail psoriasis is considered as the precursor of severe inflammatory joint 
disorders, and it has a positive correlation with the joint involvement [30]. The 
presence of the joint and nail symptoms may indicate the severity of psoriasis and 
affect the management of the disease. Therefore, in order to prevent the progres-
sive joint damage, the nail findings should be considered as the early symptoms of 
psoriatic arthritis especially in patients with skin psoriasis.
8. Conclusion
Psoriasis vulgaris is an inflammatory skin disease involving the skin, nails, 
and joints. Nail changes are frequent in psoriasis and being found in up to 60% of 
patients. Patients with nail psoriasis can develop a wide variety of nail changes, 
such as pitting, onycholysis, subungual hyperkeratosis, and splinter hemorrhages. 
Nail psoriasis is also strongly associated with psoriatic arthritis. Nail psoriasis 
results from psoriatic inflammation involving the nail matrix or nail bed. As the 
nail involvement pursues skin psoriasis, its diagnosis is rather easy. However, 5% 
of the cases are isolated nail psoriasis, and the diagnosis may become difficult. 
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Onychomycosis should be distinguished from nail psoriasis in the differential 
diagnosis. The decision on a treatment method depends on several factors and the 
severity of nail psoriasis.
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